UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 667,978 Shares of Illumina, Inc. $ILMN

Key Points

• UBS AM has increased its stake in Illumina, Inc. by 51.7%, now holding approximately 1.24% of the company, valued at $155.54 million.
• Illumina's stock performance includes a current price of $95.12, with a 52-week range of $68.70 to $156.66 and a market cap of $14.62 billion.
• Analysts have mixed ratings on Illumina, with a current average rating of "Hold" and a price target of $123.06.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 51.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 1,960,385 shares of the life sciences company's stock after acquiring an additional 667,978 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 1.24% of Illumina worth $155,537,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after acquiring an additional 224 shares during the period. Rakuten Securities Inc. raised its holdings in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after buying an additional 270 shares during the period. Center for Financial Planning Inc. purchased a new stake in Illumina during the first quarter worth about $33,000. Fourth Dimension Wealth LLC purchased a new stake in Illumina during the fourth quarter worth about $40,000. Finally, PFS Partners LLC increased its stake in Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

ILMN stock traded up $1.53 during trading on Thursday, reaching $102.40. 328,930 shares of the company's stock were exchanged, compared to its average volume of 2,232,621. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The company's fifty day moving average price is $99.65 and its 200-day moving average price is $88.78. The firm has a market cap of $15.74 billion, a PE ratio of 12.98, a P/E/G ratio of 2.28 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ILMN. Citigroup downgraded Illumina from a "hold" rating to a "strong sell" rating and lowered their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Stephens set a $110.00 price objective on Illumina and gave the company an "overweight" rating in a research note on Monday, August 4th. Canaccord Genuity Group boosted their price objective on Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Wall Street Zen cut Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Robert W. Baird increased their price objective on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research report on Monday, July 28th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $123.06.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.